Dana-Farber Cancer Institute

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Dana-Farber Cancer Institute
May 1, 2024, 01:17 | Blog
Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published
Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:…
Apr 30, 2024, 12:22 | Insight
Harold Burstein: ER-low tumors will require chemotherapy and endocrine therapy
Harold Burstein, Breast Cancer Specialist and Professor at Dana Farber Cancer Institute, shared a post…
Apr 29, 2024, 15:12 | Blog
Damon Runyon Cancer Research Foundation 2024 Quantitative Biology Fellow - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on LinkedIn: "Congratulations to Dana-Farber's Ahmed Roman, PhD, who…
Apr 28, 2024, 11:48 | Drugs
Tovorafenib has now been approved for young patients with relapsed or progressive pediatric low-grade glioma - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute recently shared on LinkedIn: "For more than a decade, a collaborative team…
Apr 28, 2024, 11:19 | Blog
Paolo Tarantino: Truly groundbreaking work that turned a failed chemotherapy in one of the most active anticancer drugs ever developed
Paolo Tarantino shared a post by Florian Muller, Co-Head of Biology at Powder Gate Discovery, on…
Apr 27, 2024, 14:14 | Blog
Registration is open for NANETS. Regional NET Education Program in Providence - Yale Cancer Center
Pamela Kunz shared a post by Yale Cancer Center, on X: "Please join us for this great…
Apr 26, 2024, 17:44 | Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 26, 2024, 10:00 | Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 23, 2024, 16:24 | Blog
Renee Maria Saliby: Enthusiastic about joining Yale Traditional Internal Medicine Program after listening to the 'State of the Cancer Center' by Eric Winer
Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Apr 22, 2024, 11:46 | Blog
Paolo Tarantino: The unmissable Harvard University breast cancer course is coming back on July 11-12
Paolo Tarantino, Research Fellow at Dana Farber Cancer Institute, shared on X: "The unmissable Harvard…
Apr 22, 2024, 11:40 | Blog
Sara Tolaney: Very excited to have Aleix Prat as the Schlager Lecturer at the Harvard Breast Course in July!
Sara Tolaney shared a post by Aleix Prat, Co-Founder of Reveal Genomics, on X/Twitter, adding:…
Apr 21, 2024, 08:54 | Insight
Rana McKay wins the 2024 Christopher G. Wood Rising Star Award at IKCS Europe
Rana McKay won the 2024 Christopher G. Wood Rising Star Award at IKCS Europe, which…
Apr 20, 2024, 20:17 | Insight
Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Tumor-infiltrating lymphocytes (TILs): not…
Apr 20, 2024, 06:03 | Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Apr 20, 2024, 01:23 | Positive
Stuart H. Orkin was named one of TIME's 100 Most Influential People of 2024 - Dana-Farber News
Quoting Dana-Farber News on X/Twitter: "Congratulations to Dana-Farber Cancer Institute's Stuart H. Orkin, MD, who…
Apr 19, 2024, 08:07 | Insight
Toni Choueiri: An inspiration to all trainees
Toni Choueiri, shared a post by Ziad Bakouny, Hematology/Oncology fellow at Memorial Sloan Kettering Cancer Center,…
Apr 18, 2024, 19:48 | Blog
Join Dana-Farber Cancer Institute in Boston on June 10-12 for Cancer Immunotherapy: From Bench to Bedside and Back
Dana-Farber Cancer Institute shared a post on LinkedIn: "Join us in Boston on June 10-12 for…
Apr 18, 2024, 17:03 | Insight
Marc Eid: Stellar talk by Jacob Berchuck during Transatlantic exchange 2024
Marc Eid, Postdoctoral research fellow in Medical Oncology at the Dana-Farber Cancer Institute, shared on…
Apr 17, 2024, 11:47 | Blog
The collaboration that ultimately led to a phase II clinical trial at Massachusetts General Hospital, where Serena found her miracle - St. Baldrick's Foundation
St. Baldrick's Foundation shared a post on LinkedIn: "David DiCillo (Dave) and Michael Tucker (Mike) are…
Apr 17, 2024, 10:09 | Positive
Yaniss B.: The 3rd edition of the Transatlantic Exchanges in Oncology was a huge success!
Yaniss B, Valorisation Officer at Gustave Roussy Transfert shared on X: “The 3rd edition of the…
Apr 16, 2024, 13:22 | Blog
Toni Choueiri: And that is a wrap for the Transatlantic conference between Dana-Farber, Gustave Roussy
Toni Choueiri shared on their X/Twitter: ''And that is a wrap for the Transatlantic conference…
Apr 16, 2024, 13:14 | Blog
Rashad Nawfal: Ending the Transatlantic Exchange 2024 on a high note with an outstanding talk by Sylvan Baca
Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on their X/Twitter: ''Ending…
Apr 16, 2024, 12:58 | Drugs
Emre Yekedüz: A retrospective study from Gustave Roussy
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at Dana-Farber Cancer…
Apr 16, 2024, 11:06 | Blog
Paolo Tarantino: Outstanding presentation on MRD/ctDNA by Heather Parsons at the 3rd Transatlantic Exchange in Oncology
 Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Outstanding presentation on…
Apr 16, 2024, 02:27 | Blog
Dana-Farber Cancer Institute and Gustave Roussy are proud to share their progress in cancer treatment
Gustave Roussy shared on X/Twitter: "Launch of the Third Transatlantic exchange in Oncology in Boston. Dana-Farber…
Apr 16, 2024, 01:37 | Blog
Did you know Robert Haddad and Toni Choueiri had a competitive streak? - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on LinkedIn: “Did you know Robert Haddad and Toni…
Apr 16, 2024, 00:17 | Blog
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn: "In our latest…
Apr 15, 2024, 12:53 | Opinion
Nikhil C. Munshi: Getting MRD as an endpoint was a great partnership between academia and industry and patient organization
Nikhil C. Munshi, Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber…
Apr 14, 2024, 13:47 | Insight
Paolo Tarantino: Do patients with these small triple-negative tumors benefit from chemotherapy?
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn: "One third of…
Apr 14, 2024, 10:33 | Opinion
Elad Sharon: Designing clinical trials is all about tradeoffs
Elad Sharon, Clinical and Translational Director of Immunotherapy Toxicity Service at Dana-Farber Cancer Institute, shared…
Apr 13, 2024, 10:28 | Opinion
Toni Choueiri: Wonderful pickleball game to benefit Dana-Farber Cancer Institute and The Jimmy Fund
Toni Choueiri shared a post on LinkedIn: "Thank you Rob Gronkowski and Julian Edelman for…
Apr 12, 2024, 03:19 | Dialogues
OncoInfluencers: Dialogue with Pasi Jänne, hosted by Gevorg Tamamyan
Join us for an exciting new episode of “OncoInfluencers,” hosted by Dr. Gevorg Tamamyan. In…
Apr 11, 2024, 17:23 | Blog
Toni Choueiri: Back in business - The SOCCER ASCO game is back during ASCO24
Toni Choueiri recently shared a post on X: "Back in business: The SOCCER ASCO game…
Apr 11, 2024, 17:15 | Blog
Oyepeju Abioye: 'Precision Immuno-Oncology in NSCLC through Gender Equity Lenses', published in MDPI
Oyepeju Abioye, Oncology Clinical Research Assistant at Florez Laboratory of Dana-Farber Cancer Institute, shared on X:…
Apr 11, 2024, 12:45 | Insight
Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head and neck cancer - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on X/Twitter: "Important IMvoke010 trial could shape future research in immunotherapy…
Apr 10, 2024, 08:56 | Career
Pasi Jänne was recently recognised with the ACS 2024 Medal of Honour Award - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on LinkedIn: “Pasi Jänne, senior vice president for Translational…
Apr 10, 2024, 05:06 | Insight
Toni Choueiri: The Renee Saliby kidney cancer biomarker paper in Cancer Cell is online with a detailed tweetorial
Toni Choueiri shared a post by Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber…
Apr 10, 2024, 05:00 | Blog
Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Our study…
Apr 9, 2024, 13:33 | Blog
Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''If you are at…
Apr 8, 2024, 23:10 | Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
Apr 8, 2024, 22:02 | Insight
Renee Maria Saliby: Our paper 'Impact of RCC molecular subtypes on immunotherapy and targeted therapy outcomes' is now published in Cancer Cell
Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Apr 8, 2024, 11:46 | Blog
Elad Sharon: Listening to my mentee, Rafeh Naqash, present some incredible data at the ⁦SWOG plenary!
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared a post on X: "Listening to…
Apr 8, 2024, 03:54 | Drugs
Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Apr 4, 2024, 13:16 | Blog
Gevorg Tamamyan: It was a great pleasure interviewing Pasi Jänne
Gevorg Tamamyan shared on LinkedIn: "It was a great pleasure interviewing Pasi Jänne, a world-known…
Apr 2, 2024, 05:37 | Drugs
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Apr 1, 2024, 23:34 | Opinion
Harold Burstein: What the Princess of Wales can teach us all about a cancer diagnosis
Harold Burstein, Breast cancer specialist and professor Dana-Farber Cancer Institute and Harvard Medical School, shared…
Mar 31, 2024, 14:23 | Blog
Dana-Farber Cancer Institute: Five Dana-Farber scientists have been chosen to receive Wong Family Awards in Translational Oncology for fiscal year 2024
Dana-Farber Cancer Institute posted on LinkedIn: "Five Dana-Farber scientists have been chosen to receive Wong…
Mar 30, 2024, 14:12 | Blog
Jennifer Buell: I ride in the Pan Mass Challenge to eliminate the premature loss of so many important lives, to stand with our fighters, to illuminate hope
Jennifer Buell, the President and Chief Executive Officer of MiNK Therapeutics, shared on LinkedIn: "I…
Mar 28, 2024, 13:57 | Blog
Dana-Farber Cancer Institute Earns Fifth Consecutive 𝗠𝗮𝗴𝗻𝗲𝘁® Designation
Dana-Farber Cancer Institute made the following on LinkedIn: “𝗗𝗮𝗻𝗮-𝗙𝗮𝗿𝗯𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗘𝗮𝗿𝗻𝘀 𝗙𝗶𝗳𝘁𝗵 𝗖𝗼𝗻𝘀𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗠𝗮𝗴𝗻𝗲𝘁® 𝗗𝗲𝘀𝗶𝗴𝗻𝗮𝘁𝗶𝗼𝗻…
Mar 27, 2024, 14:11 | Blog
Stephen V Liu: ELCC24 Great discussion of Antibody drug conjugates toxicity from Dr. Jarushka Naidoo, noting that each component of the antibody drug conjugate will impact toxicity
Mar 27, 2024, 14:04 | Blog
Idalid Franco: Applications for CancerGRACE's Patient Education Ambassador Program are open
Idalid Franco shared a post by CancerGRACE on X, adding: "Applications for CancerGRACE's Patient Education…
Mar 26, 2024, 18:28 | Blog
Ines Vaz-Luis Receives the 2024 ASCO International Women Who Conquer Cancer Mentorship Award 
The American Society of Clinical Oncology (ASCO) has announced Ines Vaz-Luis, MD, PhD, as the recipient of…
Mar 26, 2024, 05:00 | Blog
Toni Choueiri: Major Victory for kidney cancer research Funding! 50 million Dollars Awarded!
Toni Choueiri, Professor of Medicine at Harvard Medical School and Director of the Lank Center…
Mar 25, 2024, 15:55 | Career
Philip Kantoff Receives the 2024 ASCO Excellence in Teaching Award
The American Society of Clinical Oncology (ASCO) has announced Philip Kantoff, MD as the recipient of…
Mar 24, 2024, 08:23 | Drugs
Paolo Tarantino: Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Mar 22, 2024, 06:12 | Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
Mar 22, 2024, 06:06 | Blog
Cathy Wu selected for the prestigious Sjöberg Prize for her pioneering research in personalized cancer vaccines - Dana-Farber Cancer Institute
Ron DePinho, Professor of the Department of Cancer Biology, Harry Graves Burkhart III Distinguished University…
Mar 15, 2024, 18:24 | Drugs
Paolo Tarantino: Final analysis of the PEONY phase 3 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Mar 3, 2024, 06:13 | Blog
A sneak peek into Narjust Florez's unwavering focus on pregnancy and lung cancer - Florez Lab
Florez Lab shared a post on X/Twitter: ''Just published by Dana-Farber Cancer Institute: 'Guiding Lung…
Feb 29, 2024, 14:42 | Insight
Researchers at Dana-Farber Cancer Institute and the University of Trento have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma - Dana-Farber Cancer Institute
Feb 22, 2024, 10:58 | Blog
Toni Choueiri: The 3rd transatlantic exchanges between Dana-Farber Cancer Institute and Gustave Roussy happening on April 12
Toni Choueiri, Senior Executive and Chief of Genitourinary Cancers at Dana-Farber Cancer Institute, shared a…
Feb 19, 2024, 14:16 | Blog
The inaugural Oncology Symposium at Arab Health was a great success - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute made the following on LinkedIn: "We are pleased to share that the…
Feb 19, 2024, 09:20 | Insight
Brandon Huffman: Exciting translational work happening at Dana-Farber Cancer Institute
Brandon Huffman, Medical Oncologist in the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, shared an…
Feb 19, 2024, 07:17 | Career
Paolo Tarantino: Honored to be awarded a Terri Brodeur Foundation 2024 Grant
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared on X/Twitter: "Honored…
Feb 18, 2024, 10:50 | Blog
Congratulations to Dana-Farber researchers who are among 36 recipients of the ASH 2024 Scholar Awards - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute recently shared a post on LinkedIn: "Congratulations to Dana-Farber researchers Erin Parry,…
Feb 17, 2024, 10:23 | Blog
Staff from the International Patient Center (IPC) at Dana-Farber share a moment of joy after Laurie H. Glimcher ceremoniously cut a blue ribbon to mark its official opening on Jan. 16 - Dana-Farber Cancer Institute
Feb 8, 2024, 17:54 | Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Feb 1, 2024, 15:19 | Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 31, 2024, 15:28 | Blog
Jennifer Thalappillil: So excited to be joining the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute as a Scientist focused on scientific writing!
Jennifer Thalappillil, Scientific Writer at Dana-Farber Cancer Institute, shared a post on X/Twitter: "So excited…
Jan 29, 2024, 13:37 | Blog
Sarah Sammons: Learning about Leptomeningeal Disease in Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber's Breast Oncology Center, shared a post on X/Twitter:…
Jan 28, 2024, 18:44 | Blog
Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas - Dana-Farber News
Dana-Farber News recently shared a post on their X/Twitter page: "ASCO GU24: Interim phase 1…
Jan 21, 2024, 18:43 | Blog
Charles Roberts: Pediatric Cancer Dependencies Accelerator has already identified mechanistic, and potentially therapeutic, insights in cancers
Charles Roberts, Executive Vice President at St. Jude’s Research Hospital, shared a post by Association…
Jan 19, 2024, 14:06 | Insight
Mark Awad: Our group's effort to elucidate mechanisms of resistance to PD-1 immunotherapy in lung cancer
Mark Awad, Director of Clinical Research, Associate Professor of Thoracic Oncology at the Dana-Farber Cancer…
Jan 18, 2024, 15:21 | Blog
Doug Rubinson: Dana-Farber is creating a Senior VP position in medical education and seeking MD applicants
Doug Rubinson, Assistant Professor at Dana-Farber Cancer Institute, recently shared on LinkedIn: "There is a…
Jan 16, 2024, 17:14 | Career
Karen Knudsen: Dr. Janne has revolutionized understanding and treatment of lung cancer
Karen Knudsen shared on X: "Magical evening last night in DC as we celebrated the…
Jan 13, 2024, 09:58 | Blog
Congratulations to Narjust Florez on winning the Dana-Farber Cancer Institute Medical Oncology Team Science Award - Florez Lab
Florez Lab shared a post on their X/Twitter page: "Congratulations to Narjust Florez on winning…
Jan 7, 2024, 15:14 | Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Jan 4, 2024, 16:32 | Blog
Despite her nerves, she got in - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post LinkedIn: “Chief of the Division of Stem Cell Transplantation…
Dec 30, 2023, 17:51 | Opinion
Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
Dec 30, 2023, 17:29 | Blog
Paolo Tarantino: Ikigai
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
Dec 24, 2023, 18:54 | Drugs
Laurie Glimcher: Belzutifan is approved by the FDA
Laurie Glimcher, President and CEO of Dana-Farber Cancer Institute, shared on X/Twitter: "Exciting news that…
Dec 18, 2023, 21:06 | Insight
Toni Choueiri: A new option for our Kidney Cancer patients!
Toni Choueiri shared on LinkedIn: "JUST IN: FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell…
Dec 13, 2023, 16:21 | Blog
We are joining forces with Dana-Farber Cancer Institute’s Hale Family Center for Pancreatic Research - Harbinger Health
Harbinger Health shared on their LinkedIn page: ''We are joining forces with Dana-Farber Cancer Institute’s…
Dec 10, 2023, 17:26 | Career
Mark Awad was honored by GO2 for Lung Cancer at the 18th Annual Simply the Best Gala - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute posted on LinkedIn: "Congratulations to Mark Awad, MD, PhD who was honored…
Dec 8, 2023, 17:54 | Career
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Dana-Farber News /Dana Farber Cancer Institute/ shared on their X/Twitter account: "Congrats to Dana-Farber Cancer…
Nov 29, 2023, 16:26 | Blog
Top 10 abstracts to keep an eye on for SABCS 23 by Paolo Tarantino
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter: "10 days to…
Nov 25, 2023, 10:34 | Blog
Katya Losk: Dana-Farber Cancer Institute was honored to participate in the 3rd Joint Symposium on Academic Development held at the First Affiliated Hospital, Sun Yat-sen University in Guangzhou, China
Nov 24, 2023, 00:35 | Blog
Congratulations to Zuzana Tothova, MD, PhD who is the recipient of the Doris Duke Foundation's Paragon Award for Research Excellence! - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, made the following post on LinkedIn: "Congratulations to Zuzana Tothova, MD, PhD…
Nov 20, 2023, 04:08 | Insight
Adam C Palmer: You don’t need ‘1+1 makes 3’ if you can have ‘5+5 makes 10’
David Steensma, Chief Medical Officer at Ajax Therapeutics, and Anthony Letai, Professor at Dana-Farber Cancer…
Nov 8, 2023, 18:09 | Societies
ASCO has been awarded an $11 million grant from PCORI to support a clinical trial co-led by Erica Mayer - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on LinkedIn: "The American Society of Clinical Oncology (ASCO) has been awarded an $11…
Nov 7, 2023, 18:03 | Insight
Lachelle Dawn: Excited to share our review article in Blood Journal on the Causes and Consequences of Clonal Hematopoiesis
Lachelle Dawn, Hematologist and Scientist at Dana-Farber Cancer Institute, shared on Twitter: "Excited to share…
Nov 6, 2023, 04:03 | Blog
Paolo Tarantino: Make sure not to miss our presentation of RELIEVE at the San Antonio Breast Cancer Symposium (SABCS23)
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter: "Trastuzumab Deruxtecan (T-DXd)…
Oct 28, 2023, 15:53 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 10
Our 2023 OncoDaily series on '100 Influential Women in Oncology: Key Opinion Leaders to Follow…
Oct 21, 2023, 21:40 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 9
We continue OncoDaily’s ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social…
Oct 20, 2023, 20:02 | Insight
10 ESMO23 breast cancer abstracts not to miss by Paolo Tarantino
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on Twitter: "ESMO23 will have…
Oct 20, 2023, 19:58 | Stories
The work Rosenthal had done to annotate CT scans of patients with pancreatic cancer and more by Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on LinkedIn: "As a cancer imaging fellow at Dana-Farber, Michael Rosenthal,…
Oct 13, 2023, 17:39 | Blog
Sara Tolaney: Consider applying to the Gilead Research Scholars program if you are a junior faculty member looking for funding for research in solid tumors!
Quoting Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, on…
Oct 12, 2023, 02:36 | Blog
Paolo Tarantino: Truly grateful for the kind invitation and incredibly warm welcome by the Argentinian and Patagonian associations of clinical oncology.
Quoting Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, on X/Twitter: "Truly…
Oct 7, 2023, 01:14 | Blog
Fadelu is being honored by HMS for his global work through Dana-Farber's collaboration with the Butaro Cancer Center for Excellence (BCCOE). - Dana-Farber Cancer Institute
Oct 3, 2023, 23:45 | Insight
Researchers at Dana-Farber Cancer Institute and Boston Medical Center conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single-cell resolution. - Dana-Farber Cancer Institute
All: 418 Posts: 301 - 400
Special Coverage